Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 113.93% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.29M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.29M.
Undervalued
The company’s latest PE is -18.63, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 6.18M shares, increasing 16.17% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.83.